Kon Elizaveta, Filardo Giuseppe, Di Matteo Berardo, Marcacci Maurilio
Nano-Biotechnology Laboratory, Rizzoli Orthopaedic Institute, Via di Barbiano n. 1/10, 40136, Bologna, Italy.
Open Orthop J. 2013 May 3;7:120-8. doi: 10.2174/1874325001307010120. Print 2013.
In recent years biological strategies are being more widely used to treat cartilage lesions. One of the most exploited novel treatments is Platelet-rich Plasma (PRP), whose high content of growth factors is supposed to determine a regenerative stimulus to cartilaginous tissue. Despite many promising in vitro and in vivo studies, when discussing clinical application a clear indication for the use of PRP cannot be assessed. There are initial encouraging clinical data, but only a few randomized controlled trials have been published, so it is not possible to fully endorse this kind of approach for the treatment of cartilage pathology. Furthermore, study comparison is very difficult due to the great variability in PRP preparation methods, cell content and concentration, storage modalities, activation methods and even application protocols. These factors partially explain the lack of high quality controlled trials up to now. This paper discusses the main aspects concerning the basic biology of PRP, the principal sources of variability, and summarizes the available literature on PRP use, both in surgical and conservative treatments. Based on current evidence, PRP treatment should only be indicated for low-grade cartilage degeneration and in case of failure of more traditional conservative approaches.
近年来,生物策略被更广泛地用于治疗软骨损伤。最常用的新型治疗方法之一是富血小板血浆(PRP),其高含量的生长因子被认为能对软骨组织产生再生刺激。尽管有许多前景良好的体外和体内研究,但在讨论临床应用时,PRP的使用尚无明确指征。有初步令人鼓舞的临床数据,但仅有少数随机对照试验发表,因此无法完全认可这种治疗软骨病变的方法。此外,由于PRP制备方法、细胞含量和浓度、储存方式、激活方法甚至应用方案存在很大差异,研究比较非常困难。这些因素部分解释了迄今为止高质量对照试验的缺乏。本文讨论了PRP基础生物学的主要方面、主要变异来源,并总结了PRP在手术和保守治疗中应用的现有文献。基于目前的证据,PRP治疗仅适用于低度软骨退变以及更传统保守方法治疗失败的情况。